2-trimethylsilanyloxy-propylamine | 17067-54-8

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 2-trimethylsilanyloxy-propylamine
• 英文别名: 2-trimethylsilyloxypropan-1-amine
• CAS: 17067-54-8
• 化学式: C₆H₁₇NOSi
• mdl: MFCD19203849
• 分子量: 147.293
• InChiKey: ZPRPHYOYEXYXBS-UHFFFAOYSA-N

物化性质

• 沸点：
  128-130 °C
• 密度：
  0.874 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.19
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-trimethylsilanyloxy-propylamine 、 对氯苯磺酰异氰酸酯 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  Acetylative cleavage of (arylsulfonyl)ureas to N-acetylarenesulfonamides and isocyanates

  摘要：

  DOI：

  10.1021/jo00224a077
• 作为产物：
  描述：

  在 盐酸 作用下， 以 甲醇 为溶剂， 生成 2-trimethylsilanyloxy-propylamine
  参考文献：
  名称：

  Calas,R. et al., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1967, vol. 265, p. 516 - 518

  摘要：

  DOI：

文献信息

• Regiochemical switching of Mitsunobu cyclisation mode of vicinal diamines with pendant hydroxyl group
  作者：James C. Anderson、Helen A. Chapman

  DOI：10.1039/b705081j

  日期：——

  Ambident 1,2-diamines derived from the nitro-Mannich reaction containing both a tosyl amide and a secondary amine could be regioselectively cyclised through the tosyl amide onto a pendant primary hydroxyl group to give piperazine (60–75% yields) or 1,4-diazepane (71% yield) ring systems under Mitsunobu conditions. For some substrates addition of Et3N·HCl encouraged regioselective cyclisation through the secondary amine leading to aziridine ring systems.

  含有甲苯磺酰胺和二级胺的双齿1,2-二胺，源自硝基-曼尼希反应的产物，可以在三苯膦条件下，通过甲苯磺酰胺选择性地环化到一个悬挂的一级羟基上，得到哌嗪（60-75%产率）或1,4-二氮杂环庚烷（71%产率）环系统。对于某些底物，添加Et3N·HCl会促使通过二级胺进行选择性环化，导致氮杂环丁烷环系统的形成。
• 1,2,3-THIADIAZOL-5YL-UREA DERIVATIVES, USE THEREOF FOR REGULATING PLANT SENESCENCE AND PREPARATIONS CONTAINING THESE DERIVATIVES
  申请人：USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I.

  公开号：US20170280721A1

  公开（公告）日：2017-10-05

  Substituted 1,2,3-thiadiazol-5yl-urea derivatives, their use as anti-senescence and anti-stress factors of plant cells, organs and the whole plant, and preparations containing these derivatives.

  1,2,3-噻二唑-5基脲衍生物，其作为植物细胞、器官和整株植物的抗衰老和抗压力因子的用途，以及含有这些衍生物的制剂。
• Low viscosity alkanolguanidine and alkanolamidine liquids for CO₂capture
  作者：Phillip K. Koech、Jian Zhang、Igor V. Kutnyakov、Lelia Cosimbescu、Suh-Jane Lee、Mark E. Bowden、Tricia D. Smurthwaite、David J. Heldebrant

  DOI：10.1039/c2ra22801g

  日期：——

  Global carbon dioxide (CO2) emission is expected to increase tremendously with the shift to coal-powered plants for energy generation. Capture and sequestration of CO2 are needed to mitigate environmental effects. Solvents currently used for this are the energy-intensive aqueous amines. Here we present 10 advanced solvents called alkanolguanidines and alkanolamidines that are potentially energy-efficient CO2-capture solvents. These solvents were synthesized in 1–3 steps from commercially available materials. One alkanolamidine derived from a 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) base core has a low vapor pressure and a high viscosity, resulting in low CO2 uptake capacity at standard temperature and pressure (STP). Three imidazoline base derived alkanolamidines were non-viscous but do not bind CO2 at STP, however, under mild pressure they effectively capture 7–10 wt%, making them suitable for high-pressure CO2 capture. Six novel alkanolguanidine molecules have low vapor pressure and low viscosity (<10 cP) which enable high CO2 uptake at STP. These compounds bind CO2 chemically via the alcohol moiety forming zwitterionic guanidinium and amidinium alkylcarbonate ionic liquids. These materials can be regenerated thermally by heating the alkylcarbonate to 75 °C. CO2 binding capacities of up to 12 wt% were achieved using several of these compounds at STP. Through this study we found that alkanolguanidines have low viscosity, are non-volatile, have high CO2 uptake at STP and are tolerant to water; thus we selected one compound for physical property testing.

  随着能源生产转向煤电厂，全球二氧化碳（CO2）排放量预计将大幅增加。需要对二氧化碳进行捕集和封存，以减轻对环境的影响。目前用于此目的的溶剂是高能耗的水胺。在此，我们介绍了 10 种名为烷醇胍和烷醇酰胺的先进溶剂，它们可能是高效节能的二氧化碳捕集溶剂。这些溶剂是用市场上可买到的材料通过 1-3 个步骤合成的。其中一种由 1,8-二氮杂双环[5.4.0]-十一碳-7-烯（DBU）基核衍生的烷醇脒具有低蒸汽压和高粘度，因此在标准温度和压力（STP）下的二氧化碳吸收能力较低。三种由咪唑啉基衍生的烷醇酰胺不具粘性，但在标准温度和压力下不结合二氧化碳，不过，在温和的压力下，它们能有效捕获 7-10 wt%的二氧化碳，因此适用于高压二氧化碳捕获。六种新型烷醇胍分子具有低蒸气压和低粘度（<10 cP），可在 STP 时吸收大量二氧化碳。这些化合物通过醇分子与二氧化碳发生化学结合，形成齐聚物胍和脒烷基碳酸酯离子液体。通过将烷基碳酸酯加热到 75 °C，可对这些材料进行热再生。在 STP 条件下，使用其中几种化合物可实现高达 12 wt% 的二氧化碳结合能力。通过这项研究，我们发现烷醇胍的粘度低、不易挥发、在 STP 条件下具有较高的二氧化碳吸收能力，并且耐水；因此我们选择了一种化合物进行物理性质测试。
• Benzoxepin PI3K inhibitor compounds and methods of use
  申请人：F. Hoffman-La Roche AG

  公开号：US08263633B2

  公开（公告）日：2012-09-11

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C（R7）2，（x）X1为C（R7）2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，对于抑制脂质激酶包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病是有用的。公式I化合物的使用方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病，或相关的病理条件。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噻吩化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；当(i) X1为N且X2为S，(ii) X1为S且X2为N，(iii) X1为CR7且X2为S，(iv) X1为S且X2为CR7，(v) X1为NR8且X2为N，(vi) X1为N且X2为NR8，(vii) X1为CR7且X2为O，(viii) X1为O且X2为CR7，(ix) X1为CR7且X2为C(R7)2，(x) X1为C(R7)2且X2为CR7，(xi) X1为N且X2为O，或(xii) X1为O且X2为N，对于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病有用。本文还公开了使用公式I化合物在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。